Tenaya Therapeutics Appoints New CMO, Dr. Cook
Ticker: TNYA · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1858848
| Field | Detail |
|---|---|
| Company | Tenaya Therapeutics, Inc. (TNYA) |
| Form Type | 8-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $3.00, $3.06, $15.19, $1.21 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Tenaya swapped CMOs, bringing in Dr. Cook to lead the charge.
AI Summary
Tenaya Therapeutics, Inc. announced on January 24, 2025, the departure of its Chief Medical Officer, Dr. Faraz Ali. The company also announced the appointment of Dr. Jennifer L. Cook as the new Chief Medical Officer, effective January 24, 2025. Additionally, the company reported on compensatory arrangements for certain officers.
Why It Matters
A change in Chief Medical Officer can signal shifts in the company's R&D strategy and pipeline development, impacting investor confidence and future drug approvals.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can introduce uncertainty regarding the company's strategic direction and execution.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- Dr. Faraz Ali (person) — Departing Chief Medical Officer
- Dr. Jennifer L. Cook (person) — Appointed Chief Medical Officer
- January 24, 2025 (date) — Effective date of changes
FAQ
Who is the new Chief Medical Officer at Tenaya Therapeutics?
Dr. Jennifer L. Cook was appointed as the new Chief Medical Officer, effective January 24, 2025.
Who previously held the Chief Medical Officer position?
Dr. Faraz Ali was the Chief Medical Officer who departed from Tenaya Therapeutics.
When did these changes take effect?
The changes, including the appointment of Dr. Cook and the departure of Dr. Ali, were effective as of January 24, 2025.
What is Tenaya Therapeutics' primary business?
Tenaya Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances).
What is the principal executive office address for Tenaya Therapeutics?
The principal executive offices are located at 171 Oyster Point Boulevard, Suite 500, South San Francisco, California, 94080.
Filing Stats: 886 words · 4 min read · ~3 pages · Grade level 14.8 · Accepted 2025-01-28 17:12:47
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select
- $3.00 — rice per share equal to or greater than $3.00 (the "Eligible Options"). The reprice
- $3.06 — h original exercise prices ranging from $3.06 to $15.19 per share). The new exercis
- $15.19 — l exercise prices ranging from $3.06 to $15.19 per share). The new exercise price fo
- $1.21 — exercise price for repriced options is $1.21 per share, the closing price of the Com
- $21.01 — d exercise prices ranging from $3.06 to $21.01 per share. SIGNATURES Pursuant to t
Filing Documents
- tnya-20250124.htm (8-K) — 48KB
- 0000950170-25-009946.txt ( ) — 164KB
- tnya-20250124.xsd (EX-101.SCH) — 25KB
- tnya-20250124_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Jennifer Drimmer Rokovich Jennifer Drimmer Rokovich General Counsel and Secretary Date: January 28, 2025